<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="may include thrombocytopenia, anemia, abnormal liver and kidney function, elevated" exact="creatine" post="kinase and prothrombin time, increased lactate dehydrogenase and D-dimer."/>
 <result pre="care, and to minimize complications. Non-steroidal anti-inflammatory drugs (NSAIDs), including" exact="ibuprofen" post="use, have been reported with clinical deterioration in some"/>
 <result pre="indicated an increase of viral shedding [40]. However, treatment with" exact="methylprednisolone" post="may be beneficial for patients who develop acute respiratory"/>
 <result pre="have currently been conducted investigating the potential cure effect, including" exact="hydroxychloroquine" post="in combination with azithromycin, immune therapy, remdesivir, different antiviral"/>
 <result pre="serious cardiac side effects, treating physicians must be aware of." exact="Chloroquine" post="and hydroxychloroquine, which is the more potent synthetic form"/>
 <result pre="of COVID-19 based on a small French trial [42, 43]." exact="Chloroquine" post="can cause atrioventricular (AV) block and, along with azithromycin,"/>
 <result pre="atrioventricular (AV) block and, along with azithromycin, prolonged QT interval." exact="Hydroxychloroquine" post="can similarly produce conduction problems in the heart. Additive"/>
 <result pre="[49]. A recent multicenter, open-label, randomized controlled trial (RCT) of" exact="hydroxychloroquine" post="involving 150 adults admitted to hospital for COVID-19 reported"/>
 <result pre="the active metabolites of clopidogrel, prasugrel while increasing that of" exact="ticagrelor" post="as well as increasing statins levels with risk of"/>
 <result pre="Lopinavir/ritonavir potentiates the effects of factor Xa inhibitors such as" exact="apixaban" post="and rivaroxaban through the inhibition of CYP3A4, thereby increasing"/>
 <result pre="the effects of factor Xa inhibitors such as apixaban and" exact="rivaroxaban" post="through the inhibition of CYP3A4, thereby increasing bleeding risk"/>
 <result pre="treatment benefit [51]. Remdesivir is a monophosphoramidate prodrug of an" exact="adenosine" post="analogue that inhibits viral RNA synthesis with a broad"/>
 <result pre="with COVID-19 in Wuhan, China. JAMA Cardiol. 2020. 10.1001/jamacardio.2020.0950. 39.DayMCovid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="2020:ciaa237 10.1093/cid/ciaa237. 43.Gautret P, Lagier JC, Parola P, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
 <result pre="43.Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="a scientific statement from the American Heart AssociationCirculation.2016134e32e6910.1161/CIR.000000000000042627400984 48.SvanstrÃ¶mHPasternakBHviidAUse of" exact="azithromycin" post="and death from cardiovascular causesN Engl J Med20133681704171210.1056/NEJMoa130079923635050 49.XiongTYRedwoodSPrendergastBChenMCoronaviruses"/>
 <result pre="Heart J2020191798180010.1093/eurheartj/ehaa231 50.Tang W, Cao Zhu, Han M, et al." exact="Hydroxychloroquine" post="in patients with COVID-19: an open-label, randomized, controlled trial."/>
</results>
